health information is crucial for healthcare professionals to improve their
knowledge in providing healthcare services. During a series of talks at the
IMPACT GP Symposium 2020 held in Singapore on 11 January 2020, a panel of
specialists shared insights on current treatment approaches for atopic
dermatitis and wound healing, as well as updates from the 2019 dyslipidaemia
guidelines and on the management of fatty liver disease.
Systemic therapy plays a central role in the management of unresectable hepatocellular carcinoma (HCC). In this rapidly developing therapy area, recent clinical trials are redefining systemic treatments, including multiple kinase inhibitors (MKI). During the recent Gastro Lunch and Learn sessions sponsored by Eisai, Dr David Tai and Dr Yong Wei Peng discussed the evidence behind MKIs such as lenvatinib (Lenvima®) in the treatment of unresectable HCC through a case-based approach.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 20190910083343
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Overall survival (OS) is currently the primary
criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant
medical oncologist at the National University Hospital, Singapore, details the
crucial role played by tumour response in evaluating treatment efficacy, with a
focus on the multiple kinase inhibitor lenvatinib in the treatment of
hepatocellular carcinoma (HCC).
Current guidelines for the treatment of chronic hepatitis B (CHB)
recommend entecavir (ETV), tenofovir disoproxil fumarate (TDF), or
tenofovir alafenamide (TAF) as first-line oral agents. [Hepatology
2018;67:1560-1599; Hepatol Int 2016;10:1-98; J Hepatol 2017;67:370-398]
TAF, like TDF, is a phosphonate prodrug of tenofovir. Whether tenofovir
is superior to entecavir in specific clinical settings, or both
antivirals have comparable clinical outcomes in real-world cohorts,
remains to be extensively studied as these would have considerable
implications for practice and the prevention of hepatocellular carcinoma
(HCC) in the CHB population.